Literature DB >> 17007229

Electroconvulsive therapy in older adults: 13-year trends.

Mark Jeffrey Rapoport1, Muhammad Mamdani, Nathan Herrmann.   

Abstract

OBJECTIVES: To examine temporal trends in electroconvulsive therapy (ECT) use among all 12 million Ontario residents between January 1992 and December 2004 and to examine the differential trends in older adults, compared with younger ones.
METHODS: We undertook a time-series analysis to examine annual trends in the use and prevalence of ECT, using linked provincial datasets. Descriptive data were presented for the population as a whole, and then trends were described separately by age groups (younger and older). As a comparator, we similarly examined antidepressant prevalence for older adults over the same time period.
RESULTS: Overall rates of ECT prevalence were stable. Annual population rates of individuals receiving ECT increased by about 27%, from 12.3 per 100 000 population in 1992 to 15.6 per 100 000 in 1997, and then decreased to 12.5 per 100 000 by 2004. The population rates of ECT were about threefold higher among older adults, relative to the younger population. Antidepressant prevalence increased by 90.1% among older adults over the same time period. The female-to-male ratio was relatively stable over time.
CONCLUSIONS: The rate of ECT has been relatively stable since the early 1990s. Older adults were much more likely to be prescribed a course of ECT than younger adults. ECT remains a commonly prescribed treatment, particularly in old age.

Mesh:

Year:  2006        PMID: 17007229     DOI: 10.1177/070674370605100910

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  6 in total

Review 1.  Neuromodulation for treatment-refractory major depressive disorder.

Authors:  Nir Lipsman; Tejas Sankar; Jonathan Downar; Sidney H Kennedy; Andres M Lozano; Peter Giacobbe
Journal:  CMAJ       Date:  2013-07-29       Impact factor: 8.262

2.  Declining use of electroconvulsive therapy in United States general hospitals.

Authors:  Brady G Case; David N Bertollo; Eugene M Laska; Lawrence H Price; Carole E Siegel; Mark Olfson; Steven C Marcus
Journal:  Biol Psychiatry       Date:  2012-10-08       Impact factor: 13.382

3.  Electroconvulsive Therapy Practice in the Province of Quebec: Linked Health Administrative Data Study from 1996 to 2013.

Authors:  Morgane Lemasson; Julie Haesebaert; Louis Rochette; Eric Pelletier; Alain Lesage; Simon Patry
Journal:  Can J Psychiatry       Date:  2017-10-25       Impact factor: 4.356

Review 4.  Update on Neuromodulation for Treatment-Resistant Depression.

Authors:  Bettina Bewernick; Thomas E Schlaepfer
Journal:  F1000Res       Date:  2015-12-02

5.  Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST): protocol for identification of novel biomarkers via neurophysiology.

Authors:  Zafiris J Daskalakis; Shawn M McClintock; Itay Hadas; Elisa Kallioniemi; Reza Zomorrodi; Alanah Throop; Lucy Palmer; Faranak Farzan; Kevin E Thorpe; Carol Tamminga; Daniel M Blumberger
Journal:  Trials       Date:  2021-12-11       Impact factor: 2.279

6.  Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST): study protocol for a randomized non-inferiority trial of magnetic seizure therapy versus electroconvulsive therapy.

Authors:  Zafiris J Daskalakis; Carol Tamminga; Alanah Throop; Lucy Palmer; Julia Dimitrova; Faranak Farzan; Kevin E Thorpe; Shawn M McClintock; Daniel M Blumberger
Journal:  Trials       Date:  2021-11-08       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.